PRGN-2009 and bintrafusp alfa for patients with advanced or metastatic human papillomavirus-associated cancer

20257 citationsJournal Articlegold Open Access

Authors

Charalampos S. Floudas · National Institutes of Health

Meghali Goswami · National Institutes of Health

Renee N. Donahue · National Institutes of Health

Julius Strauss · National Institutes of Health

Danielle M. Pastor · National Institutes of Health

Jason M. Redman · National Institutes of Health

Isaac Brownell

Abstract

PRGN-2009 was well tolerated, and immune responses were observed to PRGN-2009. Encouraging anti-tumor activity and OS were noted in the combination with BA arm, consisting mainly of checkpoint-resistant patients. Trial Registration ClinicalTrials.gov Identifier: NCT04432597.

Topics & Keywords

Cancer Research and Treatments Virus-based gene therapy research Colorectal and Anal Carcinomas

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Immunology Immunotherapy

Volume 74, Issue 5, pp. 155-155

DOI: 10.1007/s00262-025-04009-z

Field-Weighted Citation Impact: 8.48